Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ZVRA, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Arimoclomol FDA approved Sep 2024 · Miplyffa |
Niemann-Pick Disease, Type C | Phase 2/3 · NCT02612129 | Completed |
| Serdexmethylphenidate And Dexmethylpheni FDA approved Mar 2021 · Azstarys |
ADHD | Phase 3 · NCT03460652 | Completed |
| Sodium Phenylbutyrate FDA approved Dec 2022 · Olpruva |
Medium-chain Acyl-CoA Dehydrogenase Deficiency | Phase 2 · NCT06773026 | Recruiting |
| Celiprolol | Vascular Ehlers-Danlos Syndrome | Phase 3 · NCT05432466 | Recruiting |
| Osanetant (ACER-801) | Post-menopausal Vasomotor Symptoms | Phase 1/2 · NCT05325775 | Completed |
| Serdexmethylphenidate | Idiopathic Hypersomnia | Phase 2 · NCT05668754 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ZVRA holds $260.2M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZVRA files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZVRA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →